3
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Hospital pharmacist's roles and responsibilities with CAR-T medicines Translated title: Funciones y responsabilidades del farmacéutico de hospital con los medicamentos CAR-T

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Abstract The development and commercialization of cell therapy drugs with chimeric antigen receptor T cells (CAR-T) represent a new challenge for Spain's hospital pharmacy. The aim of this article is to review the key aspects of these medicines and to describe the oncohematological pharmacist's role within the multidisciplinary clinical team. This includes the different phases in the transversal process that involves a therapy with CAR-T medicines, ranging from indication to short and long term follow-up of patients treated with this type of therapy, and emphasizing on the management of its main adverse effects. CAR-T therapy offers the hospital pharmacist the opportunity to work closely with the rest of the clinical professionals involved in the process, allowing their contribution to the development of procedures, clinical practice guidelines of global approach, and establishing starting points when facing future therapies of similar complexity -and even improving previously established basic processes-.

          Translated abstract

          Resumen El desarrollo y la comercialización de medicamentos de terapia celular con células T con receptor de antígeno quimérico (CAR-T) suponen un nuevo reto para la farmacia hospitalaria en España. El objetivo de este artículo es revisar los aspectos clave de estos medicamentos y describir el papel del farmacéutico oncohematológico dentro del equipo clínico multidisciplinar en las diferentes fases del proceso transversal que implica el tratamiento con medicamentos CAR-T, desde la indicación hasta el seguimiento a corto y largo plazo de los pacientes tratados con este tipo de terapias, con una importante mención al manejo de sus principales efectos adversos. La terapia tipo CAR-T ofrece al farmacéutico hospitalario la oportunidad de trabajar en estrecha colaboración con el resto de los profesionales clínicos implicados en el proceso, permitiendo su contribución en el desarrollo de procedimientos, guías de práctica clínica de abordaje global y estableciendo puntos de partida para afrontar tratamientos futuros de complejidad similar e incluso mejorar procesos base anteriormente establecidos.

          Related collections

          Most cited references2

          • Record: found
          • Abstract: not found
          • Article: not found

          The Hematopoietic Cell Transplant Pharmacist: Roles, Responsibilities, and Recommendations from the ASBMT Pharmacy Special Interest Group

            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            American Society for Blood and Marrow Transplantation Pharmacy Special Interest Group Survey on Chimeric Antigen Receptor T Cell Therapy Administrative, Logistical and Toxicity Management Practices in the United States

              Bookmark

              Author and article information

              Journal
              fh
              Farmacia Hospitalaria
              Farm Hosp.
              Grupo Aula Médica (Toledo, Toledo, Spain )
              1130-6343
              2171-8695
              February 2020
              : 44
              : 1
              : 26-31
              Affiliations
              [3] orgnameCatalan Institute of Oncology orgdiv1Pharmacy Service Spain
              [2] orgnameSant Joan de Déu Hospital orgdiv1Pharmacy Service Spain
              [1] orgnameSanta Creu i Sant Pau Hospital orgdiv1Pharmacy Service Spain
              [4] orgnameVall d'Hebron University Hospital orgdiv1Pharmacy Service Spain
              Article
              S1130-63432020000100026 S1130-6343(20)04400100026
              10.7399/fh.11333
              31901059
              5c1db809-f6b5-49f7-b6f7-4237c347367e

              This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

              History
              : 20 November 2019
              : 03 October 2019
              Page count
              Figures: 0, Tables: 0, Equations: 0, References: 16, Pages: 6
              Product

              SciELO Spain

              Categories
              Special Articles

              Atención farmacéutica,CAR-T-related encephalopathy syndrome,Pharmaceutical care,Síndrome de encefalopatía relacionada con CAR-T,Receptor antigénico quimérico de células T,Síndrome de liberación de citoquinas,T-cell chimeric antigen receptor,Cytokine release syndrome

              Comments

              Comment on this article